Join Growin Stock Community!

拉法醫6848.TW Overview

TW StockBiotech. & Medical
(No presentation for 6848)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

拉法醫（6848）Overall Performance

拉法醫（6848）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

拉法醫（6848） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

拉法醫（6848）Key Information

拉法醫（6848）Profile

RBC Bioscience Corporation researches, develops, manufactures, and sells reagents and devices for life science and molecular diagnosis in Europe, the United States, Asia, Taiwan, Africa, and Australia. It offers molecular biomedical diagnostic and research reagents, gene extraction automatic testing instruments, and gene extraction reagent tissues; automated nucleic acid extractors; and nucleic acid extraction kits. The company sells its products through distributors. RBC Bioscience Corporation was founded in 1995 and is based in New Taipei City, Taiwan.

拉法醫（6848）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
1.82
PE Ratio (TTM)
8.89
Forward PE
-
PS Ratio (TTM)
0.62
PB Ratio
0.89
Price-to-FCF
6.00
METRIC
VALUE
vs. INDUSTRY
Gross Margin
45.37%
Net Margin
6.95%
Revenue Growth (YoY)
-11.94%
Profit Growth (YoY)
-10.65%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
1.82
PE Ratio (TTM)
8.89
Forward PE
-
PS Ratio (TTM)
0.62
PB Ratio
0.89
Price-to-FCF
6.00
Gross Margin
45.37%
Net Margin
6.95%
Revenue Growth (YoY)
-11.94%
Profit Growth (YoY)
-10.65%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
default symbol

6848

拉法醫

16.20D

1.23%

(0.01)

  • When is 6848's latest earnings report released?

    The most recent financial report for 拉法醫 (6848) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6848's short-term business performance and financial health. For the latest updates on 6848's earnings releases, visit this page regularly.

  • Where does 6848 fall in the P/E River chart?

    According to historical valuation range analysis, 拉法醫 (6848)'s current price-to-earnings (P/E) ratio is 9.59, placing it in the Value zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • How much cash does 6848 have?

    At the end of the period, 拉法醫 (6848) held Total Cash and Cash Equivalents of 60.98M, accounting for 0.08 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 6848 go with three margins increasing?

    In the latest report, 拉法醫 (6848) achieved the “three margins increasing” benchmark, with a gross margin of 46.91%%, operating margin of 17.17%%, and net margin of 10.37%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 6848's profit trajectory and future growth potential.